Heart failure. Heart failure
Conditions
Interventions
Intervention 1: Intervention group: The intervention group, or those receiving empagliflozin, will take a 10 mg empagliflozin tablet daily for 2 months (equivalent to 4 courses of doxorubicin treatmen
Sponsors
Babol University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with newly diagnosed breast cancer, stage 1 to 3, who are candidates for a chemotherapy regimen containing doxorubicin. Reading and signing the informed consent form to participate in the clinical trial People over the age of 18. People who are able to consume food. Negative pregnancy test in women of childbearing age
Exclusion criteria
Exclusion criteria: A history of cancer in the past that has received cardiotoxic drugs such as doxorubicin History of chest radiotherapy LVEF less than 50% before starting treatment Being treated for heart failure and taking medications to treat heart failure History of congenital heart disease or history of coronary artery disease History of more than moderate valvular heart disease based on history and records History of hypertension or history of symptomatic hypotension or SBP less than 100 on the first or second visit History of atrial fibrillation History of cardiomyopathy and use of heart failure medications based on the medical history in the file History of stroke Cognitive and neurological disorders Simultaneous participation in another clinical trial Allergy to any of the materials used in the trial Liver disease or LFTs greater than 3 times ULN at first visit Kidney failure in the form of a GFR less than 30 or requiring dialysis, diagnosed at the first visit History of diabetic ketoacidosis History of surgery on the gastrointestinal tract or a gastrointestinal disorder that interferes with drug absorption Patients who have used SGLT2I drugs for at least 3 months before referral Alcohol or drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in echocardiographic patterns in strain echocardiography. Timepoint: Before the start of the study and one week after the last chemistry session. Method of measurement: Echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac ejection fraction (EF). Timepoint: Before the start of the study and one week after the last chemistry session. Method of measurement: Echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSahar Khosravi
Babol University of Medical Sciences
Outcome results
None listed